MannKind Corporation

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
4.79 ^USD	-0.62%		+4.36%	+31.59%

08/05	Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024
08/05	Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	MT

MannKind Corporation Announces Retirement of Nordhoff from the Audit Committee and Board

April 11, 2020 at 01:59 am IST

MannKind Corporation announced that Mr. Nordhoff will retire from the Audit Committee concurrently with his retirement from the Board at the annual meeting, to be held on May 21, 2020.

Latest news about MannKind Corporation

Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	09/05	MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M	09/05	MT
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment	06/05	MT
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	06/05	CI
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30/04	CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	29/04	MT
MannKind Gets FDA Clearance for Clofazimine IND Application	29/04	DJ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	29/04	CI
MannKind CFO Binder to Retire in April, Names New CFO	27/03	MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	27/03	CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	27/03	CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	11/03	CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	28/02
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	28/02	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	15/02	CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	12/01
Transcript : MannKind Corporation - Special Call	03/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01	MT
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million	02/01	MT
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals	28/12	MT
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing	18/12	MT
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	14/11	MT

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sector

Biotechnology & Medical Research

Calendar

22/06/2024 - American Diabetes Association Scientific Symposium

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MannKind Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.78 USD

Average target price

7.083 USD

Spread / Average Target

+48.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MANNKIND CORPORATION	+31.59%	130.17Cr
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.34TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.60%	1.81TCr
WUXI APPTEC CO., LTD.	-41.25%	1.67TCr
BEIGENE, LTD.	-15.33%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.17TCr

Bio Therapeutic Drugs